SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (704)6/27/2001 7:47:58 PM
From: Crossy  Read Replies (1) | Respond to of 1784
 
Tuck & all threadsters,
let me congratulate for your thread here. I really like your efforts here. Biotechs is my "blind spot". As much as I admire this domain of science as little do I comprehend the complex interactions at work. So I'm trying to learn.

May I raise a question too ? Since you are looking for "trickle down" biotech effects I would like to know whether just equipment suppliers qualify for this supply chain position you are looking for or if input-material sources and producers would also qualify.

For example take a company like NABI. They recently sold their antibody collection center to an Australian outfit for $150m. They became debt free but will have to live with reduced revenues, quarterly 60m down to 15m until their biotech portfolio becomes fully mature. Now I do understand that those antibody collection centers provide input material to vaccine production and related research (pls. correct me if I'm wrong). Would such a position qualify as a "trickle" play (in the case NABI didn't have their own biotech business which they do) ?

If yes then I would like to ask you (and others too) if you think that demand for substances like Protein A will increase in the market (I would think so now that so many biotech companies are out - I counted almost 500) and whether the increase would be spectacular and sustainable or just a singular event.

best wishes
CROSSY